Atrial cardiomyopathy (AtCM) has emerged as a critical clinical entity in recent years, encompassing structural, architectural, electrical, and functional abnormalities in the atria [1]. Atrial cardiomyopathy is increasingly recognized as a clinically significant condition due to its potential to contribute to atrial thrombosis, arrhythmias, functional regurgitation, and atrial failure [2–5]. Despite growing awareness, AtCM remains underdiagnosed, particularly in its early stages, especially in patients without overt structural heart disease [2].
